Aspire Pharma says that its UK launch of fluticasone propionate 400mcg 1mg/ml nasal drops “further establishes Aspire as a premier specialty generics business,” noting that the product is hitting the market in the wake of GSK pulling out, “leading to a possible short supply for patients.”
Aspire Pharma has launched fluticasone propionate 400mcg (1mg/ml) suspension nasal drops in the UK, an expansion of the firm’s respiratory portfolio that it says “further establishes Aspire as a premier specialty generics business.”
Moreover, the company noted, the launch follows “a recent discontinuation of fluticasone nasal drops by another manufacturer
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
